Nano-enabled nasal spray for osteoporosis

The University of Nottingham spin-out company, Critical Pharmaceuticals, has announced a £545,000 collaboration with the University to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis.

The University of Nottingham has world-leading capabilities in clinical and basic research in osteoporosis, geriatric care, bone pathophysiology and medical imaging. The use of University expertise for imaging drug deposition and clearance will greatly enhance the development of this formulation.

This project will draw on interdisciplinary collaborative research from international experts including Dr Richard Pearson (Division of Orthopaedic & Accident Surgery) and Professor Alan Perkins (Division of Radiological and Imaging Sciences).

See full press release.